- Datum17.07.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
XTB
J. Klatt
Moderator
Titan Pharmaceuticals Inc(Del) Aktie
Verkaufen
Kaufen
Titan Pharmaceuticals Inc(Del) Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Titan Pharmaceuticals Inc(Del) Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Baader | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,76 %
Intraday
8,43 %
1 Woche
7,20 %
1 Monat
44,68 %
Seit Jahresbeginn
-16,81 %
1 Jahr
-80,67 %
3 Jahre
-97,31 %
5 Jahre
Passender Service zu Titan Pharmaceuticals Inc(Del)
Webinar zu Titan Pharmaceuticals Inc(Del)
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,030-14,800
- Jahrestief / Hoch ($)3,030-5,760
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Titan Pharmaceuticals Inc(Del)
Keine Dividenden verfügbar
Termine von Titan Pharmaceuticals Inc(Del)
Keine aktuellen Termine
Beschreibung
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
